MergerLinks Header Logo

Announced

Completed

Jeito Capital, EcoR1 Capital and Syncona led a $110m Series A round in Neogene Therapeutics.

Synopsis

Investment companies Jeito Capital, EcoR1 Capital and Syncona led a $110m Series A round in Neogene Therapeutics, a pre-clinical stage biotechnology company, with support from Neogene’s strategic seed investors Vida Ventures, TPG and Two River. "We are extremely pleased to have made our first investment according to plan and in such a high-quality company. Neogene’s approach perfectly aligns with Jeito’s mission to support new and established entrepreneurs aspiring to help patients in need by pioneering novel, ground-breaking medicines that rethink traditional approaches. With the depth of experience of Neogene’s leadership team, the quality of its science, and its strong new and existing investor base we believe that Neogene has significant potential to transform cancer treatment for patients around the world," Rafaèle Tordjman, Jeito Founder and CEO.

Show Details & Financials

Market Context

Sort

Search a database of more than 250,000 verified dealmakers

Receive automated updates on global transactions

Follow the activity, relationships and transactions of top dealmakers

No credit card required

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US